OBJECTIVES: Analize the patient satisfaction with COPD treatment, and relation with different drugs. METHODS: Cross-sectional study of 377 patients with COPD controlled in three primary care settings. Non-random sample. Patients were cited in the health centers and were asked to answer 10 questions about satisfaction with their treatment (positive scale 1-7). In this interview the investigators carried out a spirometry. Other variables measured were: age, sex, comorbidity, and prescribed treatment. RESULTS: 331 (87.8%) males, age (mean+ std) 67.7+8.6 years, 53% had at least another comorbid condition; FEV 1 58% + 21%. In 63 patiens (15%) we couldn't find any prescribed treatment. 65% remaining received treatment with: ß 2agonist (55%), anticholinergic (30.8%), inhaled corticosteroids (35.5%), oral xantins (19.9%), oral corticosteroids (7.3%) mucolitics (21.7%) oxygen therapy (4.1%). Only 6.2% referred an adverse event with treatment. Patient satisfaction with treatment: 62% satisfied because low adverse events; 61% satisfied with drugs; 59.9% satisfied about daily life; 58.2% showed satisfaction with effects onset; 61.4% satisfied with sleep profile; 59.1% showed satisfaction with symptoms control; 60.2% satisfied with time of doses. 44% preferred to take medications once a day, 39.8% thought it's important number of time they had to take the drugs; 49.6% considered that the times to take medication in a day doesn't make it more complicated. Males feel better symptoms control than females. Satisfaction was higher in ß 2 agonist (less adverse events, less importance on times of dosage), anticholinergic drug (less adverse events, less importance on times of dosage) and inhaled corticosteroids (less adverse events). In a multivariate analisys the variables associated with satisfaction were: ß2 agonist (p=0.071) and males (p=0.051) CONCLUSION: Patient satisfaction with COPD treatment is high and is related with the low frequency of adverse events. Satisfaction is higher in males receiving treatment with ß2 agonist.